Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 17:44:44 Source:healthViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Shooting injures 2 at Missouri high school graduation ceremony
Next:US overdose deaths dropped in 2023, the first time since 2018
You may also like
- The unstoppable duo of Emma Stone and Yorgos Lanthimos
- Hong Kong, China hold Turkmenistan in FIFA World Cup qualifier
- Chinese Academy of Sciences Issues Certificates to 65 New Academicians
- China's Annual College Entrance Exam Concludes
- Inquiry slams UK authorities for failures that killed thousands in infected blood scandal
- Celebratory Atmosphere Ahead of 25th Anniv. of Hong Kong's Return to Motherland
- Farmers Busy with Summer Farming Across China
- Children Enjoy Summer Vacation Across China
- Philippines blames China for loss of giant clams in disputed shoal and urges environmental inquiry